{"name":"Moleculin Biotech","slug":"moleculin","ticker":"MBRX","exchange":"NASDAQ","domain":"moleculin.com","description":"Moleculin Biotech (MBRX) is a clinical-stage pharmaceutical company focused on the development of oncology therapeutics. The company's pipeline includes several compounds targeting various cancer types. Moleculin Biotech has a strong presence in the oncology market with its lead compounds in various stages of development.","hq":"Houston, TX","founded":0,"employees":"","ceo":"Walter V. Klemp","sector":"Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$30M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":15891000,"netIncome":-33560000,"cash":8878000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"WP1066 patent cliff ($0.0B at risk)","drug":"WP1066","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"WP122 patent cliff ($0.0B at risk)","drug":"WP122","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"WP1122","genericName":"WP1122","slug":"wp1122","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"WP1122","genericName":"WP1122","slug":"wp1122","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Moleculin Biotech Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Moleculin Biotech reported its financial results for the fourth quarter and full year 2023, highlighting its progress in clinical development and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-09-12","type":"trial","headline":"Moleculin Biotech Announces Positive Interim Results from Phase 2 Clinical Trial of WP1066 in Glioblastoma","summary":"Moleculin Biotech announced positive interim results from its Phase 2 clinical trial of WP1066 in glioblastoma, demonstrating encouraging efficacy and safety profiles.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9id0xhQmRkckhtQmM4bEtaZnlFcDZLMkIxQ2FUN21jY1oxbDRCbUpWNzJ2ZU1CUUhRNkl1OENBTXJyWEJJMThUS3VUN09yS1FocU8yVWlOSXlpby16eVRiQmozbzBRQmJGY0tETUVR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan","headline":"If You Invested $1,000 in Moleculin Biotec (MBRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNN2dIeTREcllkT1UzVDdZY2NUOEd6bUxYd3lId3lGU2t5ekVjNXhaS251amtPdGFDM0Fkb181dlhkV0h1UFlSZERNcVRpM0NmM2lZMTZGbk9SdFV3aHdHR1p1eXRYYXN1VDJuS1RhWjhfR0tGMHRlbW5NV2FQamE5OGQ0SldnUEtBaUptM2wyS1JSME5pTl95aGxIbTVRRFBCMDhURDd5UC1tY1hNRUw3V3pKVFdqVjE0UnMtb00xME9RbXd6?oc=5","date":"2026-03-22","type":"pipeline","source":"AD HOC NEWS","summary":"Moleculin Biotech stock faces bearish sentiment amid clinical-stage challenges in oncology pipeline - AD HOC NEWS","headline":"Moleculin Biotech stock faces bearish sentiment amid clinical-stage challenges in oncology pipeline","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxONlVHZUFSbV9PSGloZkNfczFFVnM1UHZOd0F3OEpTRmpZb1RTOExlZ19FUGZlMVI5TG9tbXlkbGx1WXU1c0Qyajg1cndLY3NHWVZQMkpHb0JFTG84Q0k3SHlSWVFhZlpGaVZiVHpFdXYyUEVBNDVLRWtSR2hGRzdOSzZ5NjRJSUsxV3lOLUJFeThoS1A0Y2xzZ2YxZ19hOExZOW16eUhPMjllc3k1ZDVNbW1EUFBIQ3FmbmI3Y0psNlhSNUZ6bU5lczhSbTE3NW9vcHhJWDJQQ1QyaGI0enk1Qmk0YUpWaGJ1S2V4Um9QdXE1X3gxQkVTZ0ducGtaek4zSEZ0d2FHdlMwSTNMSk45Szg0b2NDTXpZNUg4UFFsZ1RXNGMxSnRTRzdvV21JMmlDUmVaWkJnSUV0VXBFQ0NsUlk0SjAxZWJlai1scXRhNUJYQQ?oc=5","date":"2026-01-12","type":"pipeline","source":"globenewswire.com","summary":"Moleculin Accelerates Outlook Into 2026 With First Pivotal - globenewswire.com","headline":"Moleculin Accelerates Outlook Into 2026 With First Pivotal","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"WP1066","drugSlug":"wp1066","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"WP122","drugSlug":"wp122","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celldex Therapeutics","Immune Design Corp","OncoGenex Pharmaceuticals"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15891000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-33560000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":8878000,"cashHistory":[],"totalAssets":22126000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}